59 related articles for article (PubMed ID: 9293867)
21. Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.
Ghosh A; Holland AM; van den Brink MR
Immunol Rev; 2014 Jan; 257(1):226-36. PubMed ID: 24329800
[TBL] [Abstract][Full Text] [Related]
22. Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis.
Capitini CM; Nasholm NM; Duncan BB; Guimond M; Fry TJ
J Immunol; 2013 Feb; 190(3):1351-9. PubMed ID: 23275602
[TBL] [Abstract][Full Text] [Related]
23. Autocrine IFNγ controls the regulatory function of lymphoproliferative double negative T cells.
Juvet SC; Han M; Vanama R; Joe B; Kim EY; Zhao FL; Jeon C; Adeyi O; Zhang L
PLoS One; 2012; 7(10):e47732. PubMed ID: 23077665
[TBL] [Abstract][Full Text] [Related]
24. Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review.
Koreth J; Alyea EP; Murphy WJ; Welniak LA
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1502-12. PubMed ID: 19896073
[TBL] [Abstract][Full Text] [Related]
25. IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation.
Bucher C; Koch L; Vogtenhuber C; Goren E; Munger M; Panoskaltsis-Mortari A; Sivakumar P; Blazar BR
Blood; 2009 Dec; 114(26):5375-84. PubMed ID: 19843883
[TBL] [Abstract][Full Text] [Related]
26. Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease.
Rotolo JA; Stancevic B; Lu SX; Zhang J; Suh D; King CG; Kappel LW; Murphy GF; Liu C; Fuks Z; van den Brink MR; Kolesnick R
Blood; 2009 Oct; 114(17):3693-706. PubMed ID: 19666872
[TBL] [Abstract][Full Text] [Related]
27. Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.
Feng X; Hui KM; Younes HM; Brickner AG
Trends Immunol; 2008 Dec; 29(12):624-32. PubMed ID: 18952501
[TBL] [Abstract][Full Text] [Related]
28. Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vbeta use: a new paradigm for designer allogeneic blood and marrow transplantation.
Friedman TM; Goldgirsh K; Berger SA; Zilberberg J; Filicko-O'Hara J; Flomenberg N; Donato M; Rowley SD; Korngold R
Blood; 2008 Oct; 112(8):3517-25. PubMed ID: 18541718
[TBL] [Abstract][Full Text] [Related]
29. T cell repertoire complexity is conserved after LLME treatment of donor lymphocyte infusions.
Friedman TM; Filicko-O'Hara J; Mookerjee B; Wagner JL; Grosso DA; Flomenberg N; Korngold R
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1439-47. PubMed ID: 18022573
[TBL] [Abstract][Full Text] [Related]
30. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.
Chakraverty R; Eom HS; Sachs J; Buchli J; Cotter P; Hsu R; Zhao G; Sykes M
Blood; 2006 Sep; 108(6):2106-13. PubMed ID: 16757687
[TBL] [Abstract][Full Text] [Related]
31. Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model.
Jones SC; Murphy GF; Friedman TM; Korngold R
J Clin Invest; 2003 Dec; 112(12):1880-6. PubMed ID: 14679183
[TBL] [Abstract][Full Text] [Related]
32. T cell immunotherapeutic populations control viral infections in bone marrow transplant recipients.
Slobod KS; Benaim E; Woodruff L; Nooner S; Houston J; Holladay M; Lockey T; Hurwitz JL
Immunol Res; 2001; 24(3):289-301. PubMed ID: 11817326
[TBL] [Abstract][Full Text] [Related]
33. Pathogenesis of herpes simplex virus type 1-induced corneal inflammation in perforin-deficient mice.
Chang E; Galle L; Maggs D; Estes DM; Mitchell WJ
J Virol; 2000 Dec; 74(24):11832-40. PubMed ID: 11090183
[TBL] [Abstract][Full Text] [Related]
34. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
35. CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients.
Blazar BR; Taylor PA; Vallera DA
Transplantation; 1997 Aug; 64(4):571-6. PubMed ID: 9293867
[TBL] [Abstract][Full Text] [Related]
36. Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis.
Jiang Z; Podack E; Levy RB
Blood; 2001 Jul; 98(2):390-7. PubMed ID: 11435308
[TBL] [Abstract][Full Text] [Related]
37. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.
Blazar BR; Lees CJ; Martin PJ; Noelle RJ; Kwon B; Murphy W; Taylor PA
J Immunol; 2000 Nov; 165(9):4901-9. PubMed ID: 11046015
[TBL] [Abstract][Full Text] [Related]
38. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
Marks L; Altman NH; Podack ER; Levy RB
Transplantation; 2004 Mar; 77(6):804-12. PubMed ID: 15077018
[TBL] [Abstract][Full Text] [Related]
39. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
40. Biology of graft-vs.-host disease.
Korngold R
Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):18-27. PubMed ID: 8447559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
